.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 5,008,256

« Back to Dashboard

Claims for Patent: 5,008,256

Title: Salts of ranitidine and complexes of bismuth with carboxylic acids, and pharmaceutical compositions thereof
Abstract:The invention relates to salts formed between ranitidine and a complex of bismuth with a carboxylic acid, and solvates of such salts. Examples of suitable carboxylic acids are citric acid, tartaric acid and agaricic acid. The salts are useful in the treatment of gastrointestinal disorders, particularly gastroduodenal conditions. The salts show the antisecretory activity associated with ranitidine together with antibacterial activity against Campylobacter pylori and they also possess cytoprotective properties.
Inventor(s): Clitherow; John W. (Sawbridgeworth, GB2)
Assignee: Glaxo Group Limited (GB2)
Application Number:07/380,378
Patent Claims: 1. A salt formed between ranitidine and a complex of bismuth with a carboxylic acid, or a solvate of such a salt.

2. A salt according to claim 1, wherein said carboxylic acid contains at least three functional groups in the molecule in addition to the carboxyl group which is available for salt formation with ranitidine.

3. A salt according to claim 1, wherein said carboxylic acid is selected from the group consisting of citric acid, tartaric acid, ethylenediaminetetraacetic acid, propylcitric acid and agaricic acid.

4. A salt according to claim 1, wherein said carboxylic acid is selected from the group consisting of citric acid and tartaric acid.

5. A compound selected from the group consisting of N-[2-[[[5-[(dimethylamino)methyl]-2-furanyl]methyl]thio]ethyl]-N'-methyl-2 -nitro-1,1-ethenediamine 2-hydroxy-1,2,3-propanetricarboxylate bismuth (3.sup.+) complex and its solvates.

6. A compound selected from the group consisting of N-[2-[[[5-[(dimethylamino)methyl]-2-furanyl]methyl]thio]ethyl]-N'-methyl-2 -nitro-1,1-ethenediamine [(R-R*R*)]-2,3-dihydroxybutanedioate bismuth (3.sup.+) complex and its solvates.

7. A pharmaceutical composition for the treatment of a gastrointestinal disorder comprising an effective amount for treatment of said disorder of a salt formed between ranitidine and a complex of bismuth with a carboxylic acid, or a solvate of such a salt, together with at least one pharmaceutically acceptable carrier or diluent.

8. A pharmaceutical composition according to claim 7, wherein said carboxylic acid is selected from the group consisting of citric acid and tartaric acid.

9. A pharmaceutical composition according to claim 7, in a form adapted for oral administration.

10. A pharmaceutical composition for the treatment of a gastrointestinal disorder comprising an effective amount for treatment of said disorder of N-[2-[[[5-[(dimethylamino)methyl]-2-furanyl]methyl]thio]ethyl]-N'-methyl-2 -nitro-1,1-ethenediamine 2-hydroxy-1,2,3-propanetricarboxylate bismuth (3.sup.+) complex, or a solvate thereof, together with at least one pharmaceutically acceptable carrier or diluent.

11. A pharmaceutical composition according to claim 10, in unit dose form containing 100 mg to 1 g of said complex per unit dose.

12. A pharmaceutical composition according to claim 10 in unit dose form containing 100 to 800 mg of said complex per unit dose.

13. A pharmaceutical composition according to claim 10, in unit dose form containing 150 to 600 mg of said complex per unit dose.

14. A pharmaceutical composition according to claim 10 in a form adapted for oral administration.

15. A pharmaceutical composition according to claim 14 in the form of tablets.

16. A salt formed between ranitidine and a complex of bismuth with a carboxylic acid, or a solvate of such a salt, the said salt having been prepared by reacting ranitidine with a bismuth carboxylic acid complex.

17. Ranitidine bismuth citrate or a solvate thereof, when prepared by reacting ranitidine with a complex of bismuth with citric acid.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc